 NEW YORK , Jan. 25, 2023 PRNewswire -- Immunic, Inc. Nasdaq: IMUX, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in February: February 1-2: 31st Pharmacovigilance 2023 . Darius-Jean Namdjou, Ph.D. 